Since epigenetic modifications are potentially reversible, the idea was arisen that the employment of DNMT inhibitors may improve the treatment of CRCs, especially since the classic chemotherapeutic agents are of limited efficiency in the colorectal cancer treatment. This evidence concerns the gene DNMT1 and colorectal cancer.